Report cover image

Global Preventive Asthma Drug Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 197 Pages
SKU # APRC20556505

Description

Summary

According to APO Research, the global Preventive Asthma Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Preventive Asthma Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Preventive Asthma Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Preventive Asthma Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Preventive Asthma Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Preventive Asthma Drug market include Callisto Pharmaceuticals, Molecular Insight Pharmaceuticals, Xiaflex, Roche and Novartis AG, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Preventive Asthma Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Preventive Asthma Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Preventive Asthma Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Preventive Asthma Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Preventive Asthma Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Preventive Asthma Drug sales, projected growth trends, production technology, application and end-user industry.

Preventive Asthma Drug Segment by Company

Callisto Pharmaceuticals
Molecular Insight Pharmaceuticals
Xiaflex
Roche
Novartis AG
Preventive Asthma Drug Segment by Type

Somatostatin Analogs
Chemotherapy
Targeted Therapy
Preventive Asthma Drug Segment by Application

Oncology Centres
Clinics
Hospital
Preventive Asthma Drug Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Preventive Asthma Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Preventive Asthma Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Preventive Asthma Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Preventive Asthma Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Preventive Asthma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Preventive Asthma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Preventive Asthma Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Preventive Asthma Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Preventive Asthma Drug industry.
Chapter 3: Detailed analysis of Preventive Asthma Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Preventive Asthma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Preventive Asthma Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Preventive Asthma Drug Sales Value (2020-2031)
1.2.2 Global Preventive Asthma Drug Sales Volume (2020-2031)
1.2.3 Global Preventive Asthma Drug Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Preventive Asthma Drug Market Dynamics
2.1 Preventive Asthma Drug Industry Trends
2.2 Preventive Asthma Drug Industry Drivers
2.3 Preventive Asthma Drug Industry Opportunities and Challenges
2.4 Preventive Asthma Drug Industry Restraints
3 Preventive Asthma Drug Market by Company
3.1 Global Preventive Asthma Drug Company Revenue Ranking in 2024
3.2 Global Preventive Asthma Drug Revenue by Company (2020-2025)
3.3 Global Preventive Asthma Drug Sales Volume by Company (2020-2025)
3.4 Global Preventive Asthma Drug Average Price by Company (2020-2025)
3.5 Global Preventive Asthma Drug Company Ranking (2023-2025)
3.6 Global Preventive Asthma Drug Company Manufacturing Base and Headquarters
3.7 Global Preventive Asthma Drug Company Product Type and Application
3.8 Global Preventive Asthma Drug Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Preventive Asthma Drug Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Preventive Asthma Drug Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Preventive Asthma Drug Market by Type
4.1 Preventive Asthma Drug Type Introduction
4.1.1 Somatostatin Analogs
4.1.2 Chemotherapy
4.1.3 Targeted Therapy
4.2 Global Preventive Asthma Drug Sales Volume by Type
4.2.1 Global Preventive Asthma Drug Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Preventive Asthma Drug Sales Volume by Type (2020-2031)
4.2.3 Global Preventive Asthma Drug Sales Volume Share by Type (2020-2031)
4.3 Global Preventive Asthma Drug Sales Value by Type
4.3.1 Global Preventive Asthma Drug Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Preventive Asthma Drug Sales Value by Type (2020-2031)
4.3.3 Global Preventive Asthma Drug Sales Value Share by Type (2020-2031)
5 Preventive Asthma Drug Market by Application
5.1 Preventive Asthma Drug Application Introduction
5.1.1 Oncology Centres
5.1.2 Clinics
5.1.3 Hospital
5.2 Global Preventive Asthma Drug Sales Volume by Application
5.2.1 Global Preventive Asthma Drug Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Preventive Asthma Drug Sales Volume by Application (2020-2031)
5.2.3 Global Preventive Asthma Drug Sales Volume Share by Application (2020-2031)
5.3 Global Preventive Asthma Drug Sales Value by Application
5.3.1 Global Preventive Asthma Drug Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Preventive Asthma Drug Sales Value by Application (2020-2031)
5.3.3 Global Preventive Asthma Drug Sales Value Share by Application (2020-2031)
6 Preventive Asthma Drug Regional Sales and Value Analysis
6.1 Global Preventive Asthma Drug Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Preventive Asthma Drug Sales by Region (2020-2031)
6.2.1 Global Preventive Asthma Drug Sales by Region: 2020-2025
6.2.2 Global Preventive Asthma Drug Sales by Region (2026-2031)
6.3 Global Preventive Asthma Drug Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Preventive Asthma Drug Sales Value by Region (2020-2031)
6.4.1 Global Preventive Asthma Drug Sales Value by Region: 2020-2025
6.4.2 Global Preventive Asthma Drug Sales Value by Region (2026-2031)
6.5 Global Preventive Asthma Drug Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Preventive Asthma Drug Sales Value (2020-2031)
6.6.2 North America Preventive Asthma Drug Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Preventive Asthma Drug Sales Value (2020-2031)
6.7.2 Europe Preventive Asthma Drug Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Preventive Asthma Drug Sales Value (2020-2031)
6.8.2 Asia-Pacific Preventive Asthma Drug Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Preventive Asthma Drug Sales Value (2020-2031)
6.9.2 South America Preventive Asthma Drug Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Preventive Asthma Drug Sales Value (2020-2031)
6.10.2 Middle East & Africa Preventive Asthma Drug Sales Value Share by Country, 2024 VS 2031
7 Preventive Asthma Drug Country-level Sales and Value Analysis
7.1 Global Preventive Asthma Drug Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Preventive Asthma Drug Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Preventive Asthma Drug Sales by Country (2020-2031)
7.3.1 Global Preventive Asthma Drug Sales by Country (2020-2025)
7.3.2 Global Preventive Asthma Drug Sales by Country (2026-2031)
7.4 Global Preventive Asthma Drug Sales Value by Country (2020-2031)
7.4.1 Global Preventive Asthma Drug Sales Value by Country (2020-2025)
7.4.2 Global Preventive Asthma Drug Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.5.2 USA Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.6.2 Canada Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.8.2 Germany Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.9.2 France Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.9.3 France Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.11.2 Italy Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.12.2 Spain Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.13.2 Russia Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.16.2 China Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.16.3 China Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.17.2 Japan Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.19.2 India Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.19.3 India Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.20.2 Australia Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.24.2 Chile Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.26.2 Peru Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.28.2 Israel Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.29.2 UAE Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.31.2 Iran Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Preventive Asthma Drug Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Preventive Asthma Drug Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Preventive Asthma Drug Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Callisto Pharmaceuticals
8.1.1 Callisto Pharmaceuticals Comapny Information
8.1.2 Callisto Pharmaceuticals Business Overview
8.1.3 Callisto Pharmaceuticals Preventive Asthma Drug Sales, Value and Gross Margin (2020-2025)
8.1.4 Callisto Pharmaceuticals Preventive Asthma Drug Product Portfolio
8.1.5 Callisto Pharmaceuticals Recent Developments
8.2 Molecular Insight Pharmaceuticals
8.2.1 Molecular Insight Pharmaceuticals Comapny Information
8.2.2 Molecular Insight Pharmaceuticals Business Overview
8.2.3 Molecular Insight Pharmaceuticals Preventive Asthma Drug Sales, Value and Gross Margin (2020-2025)
8.2.4 Molecular Insight Pharmaceuticals Preventive Asthma Drug Product Portfolio
8.2.5 Molecular Insight Pharmaceuticals Recent Developments
8.3 Xiaflex
8.3.1 Xiaflex Comapny Information
8.3.2 Xiaflex Business Overview
8.3.3 Xiaflex Preventive Asthma Drug Sales, Value and Gross Margin (2020-2025)
8.3.4 Xiaflex Preventive Asthma Drug Product Portfolio
8.3.5 Xiaflex Recent Developments
8.4 Roche
8.4.1 Roche Comapny Information
8.4.2 Roche Business Overview
8.4.3 Roche Preventive Asthma Drug Sales, Value and Gross Margin (2020-2025)
8.4.4 Roche Preventive Asthma Drug Product Portfolio
8.4.5 Roche Recent Developments
8.5 Novartis AG
8.5.1 Novartis AG Comapny Information
8.5.2 Novartis AG Business Overview
8.5.3 Novartis AG Preventive Asthma Drug Sales, Value and Gross Margin (2020-2025)
8.5.4 Novartis AG Preventive Asthma Drug Product Portfolio
8.5.5 Novartis AG Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Preventive Asthma Drug Value Chain Analysis
9.1.1 Preventive Asthma Drug Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Preventive Asthma Drug Sales Mode & Process
9.2 Preventive Asthma Drug Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Preventive Asthma Drug Distributors
9.2.3 Preventive Asthma Drug Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.